| Immuno-genomic landscape of osteosarcoma CC Wu, HC Beird, J Andrew Livingston, S Advani, A Mitra, S Cao, ... Nature communications 11 (1), 1008, 2020 | 249 | 2020 |
| Cause of death in patients with lower‐risk myelodysplastic syndrome F Dayyani, AP Conley, SS Strom, W Stevenson, JE Cortes, G Borthakur, ... Cancer 116 (9), 2174-2179, 2010 | 225 | 2010 |
| Epidemiology and therapies for metastatic sarcoma EK Amankwah, AP Conley, DR Reed Clinical epidemiology, 147-162, 2013 | 198 | 2013 |
| Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials R Groisberg, DS Hong, A Behrang, K Hess, F Janku, S Piha-Paul, ... Journal for immunotherapy of cancer 5 (1), 100, 2017 | 163 | 2017 |
| Atezolizumab for advanced alveolar soft part sarcoma AP Chen, E Sharon, G O’Sullivan-Coyne, N Moore, JC Foster, JS Hu, ... New England Journal of Medicine 389 (10), 911-921, 2023 | 143 | 2023 |
| The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis MS Park, V Ravi, A Conley, SR Patel, JC Trent, DC Lev, AJ Lazar, ... Clinical sarcoma research 3 (1), 7, 2013 | 141 | 2013 |
| Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial N Somaiah, AP Conley, ER Parra, H Lin, B Amini, LS Soto, R Salazar, ... The Lancet Oncology 23 (9), 1156-1166, 2022 | 140 | 2022 |
| Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experience N DeVito, E Henderson, G Han, D Reed, MM Bui, R Lavey, L Robinson, ... PLoS One 10 (10), e0140362, 2015 | 121 | 2015 |
| Uterine adenosarcoma: a review MJ Nathenson, V Ravi, N Fleming, WL Wang, A Conley Current oncology reports 18 (11), 68, 2016 | 118 | 2016 |
| Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor WL Wang, A Conley, D Reynoso, L Nolden, AJ Lazar, S George, JC Trent Cancer chemotherapy and pharmacology 67 (Suppl 1), 15-24, 2011 | 103 | 2011 |
| Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas R Groisberg, DS Hong, V Holla, F Janku, S Piha-Paul, V Ravi, R Benjamin, ... Oncotarget 8 (24), 39254, 2017 | 93 | 2017 |
| Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard JA Livingston, D Bugano, A Barbo, H Lin, JE Madewell, WL Wang, ... Scientific reports 7 (1), 11836, 2017 | 91 | 2017 |
| Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes J Roszik, WL Wang, JA Livingston, CL Roland, V Ravi, C Yee, P Hwu, ... Clinical Sarcoma Research 7 (1), 11, 2017 | 90 | 2017 |
| Casting a wider net: Immunosurveillance by nonclassical MHC molecules MP D’Souza, E Adams, JD Altman, ME Birnbaum, C Boggiano, G Casorati, ... PLoS pathogens 15 (2), e1007567, 2019 | 86 | 2019 |
| Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas MJ Nathenson, AP Conley, E Sausville The oncologist 23 (1), 71-83, 2018 | 68 | 2018 |
| Progressive and reversible conduction disease with checkpoint inhibitors N Reddy, R Moudgil, JC Lopez-Mattei, K Karimzad, EN Mouhayar, ... Canadian Journal of Cardiology 33 (10), 1335. e13-1335. e15, 2017 | 63 | 2017 |
| Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma SP D’Angelo, AL Richards, AP Conley, HJ Woo, MA Dickson, M Gounder, ... Nature communications 13 (1), 3477, 2022 | 58 | 2022 |
| Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities DLF Jardim, A Conley, V Subbiah Orphanet journal of rare diseases 8 (1), 112, 2013 | 58 | 2013 |
| Outcome of first‐line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma A van Maldegem, AP Conley, P Rutkowski, SR Patel, I Lugowska, ... The Oncologist 24 (1), 110-116, 2019 | 56 | 2019 |
| Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ... J Clin Oncol 39 (15_suppl), 11519, 2021 | 55 | 2021 |
Alexander J. Lazar MD/PhDProfessor; Pathology, Genomic Medicine, Dermatology & Transl Molec Pathol, MD Anderson Cancer CtrVerified email at mdanderson.org
